Abstract
Glucose transporters (Gluts) facilitate glucose uptake and tumors frequently over express the Gluts, especially Glut-1. Breast cancer and lung cancer (NSCLC) cell lines were incubated with anti-Glut-1 antibodies alone or with cisplatin, paclitaxel or gefitinib. Inhibition of proliferation and apoptosis was assessed. Antibodies to Glut-1 inhibited proliferation by 50% and 75% in the tested NSCLC and breast cancer cell lines, respectively. They also potentiate the anti-proliferative effects of cisplatin, paclitaxel and gefitinib. Our results indicate that anti-Glut-1 antibodies inhibit proliferation and induce apoptosis in the evaluated cell lines and provide preliminary evidence of their anti-tumor activity.
MeSH terms
-
Antibodies, Monoclonal / immunology
-
Antibodies, Monoclonal / pharmacology*
-
Antineoplastic Agents / pharmacology
-
Apoptosis / drug effects*
-
Biological Transport / drug effects
-
Blotting, Western
-
Cell Line, Tumor
-
Cell Proliferation / drug effects*
-
Cisplatin / pharmacology
-
Drug Synergism
-
Gefitinib
-
Glucose / pharmacokinetics
-
Glucose Transporter Type 1 / immunology*
-
Glucose Transporter Type 1 / metabolism
-
Glucose Transporter Type 1 / physiology
-
Humans
-
Neoplasms / metabolism
-
Neoplasms / pathology
-
Neoplasms / physiopathology
-
Paclitaxel / pharmacology
-
Quinazolines / pharmacology
Substances
-
Antibodies, Monoclonal
-
Antineoplastic Agents
-
Glucose Transporter Type 1
-
Quinazolines
-
Glucose
-
Paclitaxel
-
Cisplatin
-
Gefitinib